
|Articles|December 30, 2013
Segment 1 - Introduction to NSCLC
Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC).
Advertisement
Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC). This includes the therapeutic importance of distinguishing NSCLC by histology. Dr Sugarbaker says that adenocarcinoma, squamous cell carcinoma (SCC), and large-cell carcinoma (LCC) are all considered in the broader category of NSCLC. The therapy for each of these histologies is determined by different indicators, and then classified into stages I-IV.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO
5




